Keio Innovation Initiative (KII) has made a new investment in Neusignal Therapeutics, a company developing drugs for dementia and psychiatric disorders, through a fund managed by KII. Neusignal Therapeutics’ oral small molecule drugs treat Alzheimer’s disease in its various stages of progression and enable home treatment at a low cost of care. Neusignal Therapeutics aims to create a social impact by extending healthy life expectancy and reducing economic losses by improving patient satisfaction with treatment, reducing the burden on caregivers, and contributing to the optimization of the government’s healthcare costs.

For more information, please see the press release.
https://prtimes.jp/main/html/rd/p/000000056.000018580.html